{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:45:06Z","timestamp":1791999906831,"version":"4.4.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002562","name":"Sunchon National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002562","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.dmd.2026.100356","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:43:00Z","timestamp":1782888180000},"page":"100356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Physiologically based pharmacokinetic framework for predicting CYP3A4-mediated drug-drug interactions of quetiapine with ketoconazole and carbamazepine"],"prefix":"10.1016","volume":"54","author":[{"given":"Ji-Hun","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7515-0631","authenticated-orcid":false,"given":"Seung-Hyun","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.dmd.2026.100356_bib1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/00002018-200023040-00003","article-title":"Quetiapine","volume":"23","author":"Dev","year":"2000","journal-title":"Drug Safety"},{"issue":"suppl 13","key":"10.1016\/j.dmd.2026.100356_bib2","first-page":"5","article-title":"Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing","volume":"63","author":"Nemeroff","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"10.1016\/j.dmd.2026.100356_bib3","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s40263-013-0114-6","article-title":"Clinically significant drug interactions with atypical antipsychotics","volume":"27","author":"Kennedy","year":"2013","journal-title":"CNS Drugs"},{"issue":"2-3","key":"10.1016\/j.dmd.2026.100356_bib4","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00213-010-1941-5","article-title":"Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine","volume":"213","author":"Rasmussen","year":"2011","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.dmd.2026.100356_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1742-7843.2007.00017.x","article-title":"Metabolic drug interactions with newer antipsychotics: a comparative review","volume":"100","author":"Spina","year":"2007","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100356_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.64719\/pb.4134","article-title":"Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients","volume":"40","author":"Conley","year":"2007","journal-title":"Psychopharmacol Bull"},{"issue":"1","key":"10.1016\/j.dmd.2026.100356_bib7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2125.2005.02507.x","article-title":"Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics","volume":"61","author":"Grimm","year":"2006","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.dmd.2026.100356_bib8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/17425255.2023.2278676","article-title":"Drug-drug interactions between antiseizure medications and antipsychotic medications: a narrative review and expert opinion","volume":"19","author":"Besag","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"8","key":"10.1016\/j.dmd.2026.100356_bib9","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.2174\/1570159X20666220524121645","article-title":"Pharmacokinetic interactions between antiseizure and psychiatric medications","volume":"21","author":"Zaccara","year":"2023","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100356_bib10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.dmd.2026.100356_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hup.915","article-title":"Cardiac side effects of psychiatric drugs","volume":"23","author":"Mackin","year":"2008","journal-title":"Hum Psychopharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100356_bib12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1208\/s12249-024-02995-4","article-title":"Pharmacokinetic prediction of immediate- and extended-release tablets for patients with liver disease using whole body physiologically-based pharmacokinetic modeling for the antipsychotic drug quetiapine","volume":"26","author":"Jang","year":"2024","journal-title":"AAPS PharmSciTech"},{"issue":"6","key":"10.1016\/j.dmd.2026.100356_bib13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1208\/s12248-020-00508-2","article-title":"Use of physiologically based pharmacokinetic (PBPK) modeling for predicting drug-food interactions: an industry perspective","volume":"22","author":"Riedmaier","year":"2020","journal-title":"AAPS J"},{"issue":"3","key":"10.1016\/j.dmd.2026.100356_bib14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13318-025-00938-3","article-title":"Development of a physiologically-based pharmacokinetic model for quantitative interpretation of transdermal drug delivery of rotigotine, a dopamine agonist for treating Parkinson\u2019s disease","volume":"50","author":"Jang","year":"2025","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmd.2026.100356_bib15","series-title":"Computer Aided Pharmaceutics and Drug Delivery: An Application Guide for Students and Researchers of Pharmaceutical Sciences","first-page":"255","article-title":"Physiologically based pharmacokinetic (PBPK) modelling","author":"Balhara","year":"2022"},{"issue":"11","key":"10.1016\/j.dmd.2026.100356_bib16","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3390\/pharmaceutics17111413","article-title":"The evolution and future directions of PBPK modeling in FDA regulatory review","volume":"17","author":"Li","year":"2025","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.dmd.2026.100356_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/acs.molpharmaceut.0c00903","article-title":"Physiologically based pharmacokinetic\/pharmacodynamic modeling to support waivers of in vivo clinical studies: current status, challenges, and opportunities","volume":"18","author":"Loisios-Konstantinidis","year":"2021","journal-title":"Mol Pharm"},{"issue":"11","key":"10.1016\/j.dmd.2026.100356_bib18","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1016\/j.xphs.2022.08.035","article-title":"Physiologically based pharmacokinetic (PBPK) modeling of lornoxicam: exploration of doses for CYP2C9 genotypes and patients with cirrhosis","volume":"111","author":"Jeong","year":"2022","journal-title":"J Pharm Sci"},{"issue":"12","key":"10.1016\/j.dmd.2026.100356_bib19","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/jcph.70079","article-title":"Precision pharmacokinetics of quetiapine: a physiologically based model incorporating liver cirrhosis and CYP3A4 polymorphisms","volume":"65","author":"Lee","year":"2025","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100356_bib20","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3390\/pharmaceutics15020679","article-title":"A physiologically based pharmacokinetic model of ketoconazole and its metabolites as drug\u2013drug interaction perpetrators","volume":"15","author":"Marok","year":"2023","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.dmd.2026.100356_bib21","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/pharmaceutics13020270","article-title":"Pharmacokinetics of the CYP3A4 and CYP2B6 inducer carbamazepine and its drug\u2013drug interaction potential: a physiologically based pharmacokinetic modeling approach","volume":"13","author":"Fuhr","year":"2021","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.dmd.2026.100356_bib22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11481-006-9034-2","article-title":"MDR- and CYP3A4-mediated drug\u2013drug interactions","volume":"1","author":"Pal","year":"2006","journal-title":"J Neuroimmune Pharmacol"},{"issue":"11","key":"10.1016\/j.dmd.2026.100356_bib23","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1592\/phco.22.16.1500.33697","article-title":"Elevation of carbamazepine-10, 11-epoxide by quetiapine","volume":"22","author":"Fitzgerald","year":"2002","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.dmd.2026.100356_bib25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/bdd.1899","article-title":"Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents","volume":"35","author":"Johnson","year":"2014","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.dmd.2026.100356_bib26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jad.2024.10.112","article-title":"Effect of CYP3A5\u2217 3 genotype on exposure and efficacy of quetiapine: a retrospective, cohort study","volume":"370","author":"Zhao","year":"2025","journal-title":"J Affect Disord"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:53:18Z","timestamp":1791996798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0090955626006252"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100356","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically based pharmacokinetic framework for predicting CYP3A4-mediated drug-drug interactions of quetiapine with ketoconazole and carbamazepine","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100356"}}